Posted by Michael Wonder on 12 Sep 2018
In Australia, NovaTears eye drops are available on the Pharmaceutical Benefits Scheme
12 September 2018 - Using innovative new technology, NovaTears effectively establishes a new class of treatment for evaporative dry eye.
Novaliq is the manufacturer of NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction.
AFT Pharmaceuticals commercialises NovaTears across Australasia. AFT just announced that NovaTears, its new preservative-free eye lubricant and tear film stabiliser for the treatment of evaporative dry eye, has been listed on the Australian Pharmaceutical Benefits Scheme from 1st September 2018.
